Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 975 entries
Sorted by: Best Match Show Resources per page
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.

Journal for immunotherapy of cancer

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR.
PMID: 27532020
J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016.

BACKGROUND: Preclinical studies have shown synergy between radiation therapy and immunotherapy. However, in almost all preclinical models, radiation is delivered in single doses or short courses of high doses (hypofractionated radiation). By contrast in most clinical settings, radiation is...

Cite
Crocenzi T, Cottam B, Newell P, et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016;4:45doi: 10.1186/s40425-016-0149-6.
Crocenzi, T., Cottam, B., Newell, P., Wolf, R. F., Hansen, P. D., Hammill, C., Solhjem, M. C., To, Y. Y., Greathouse, A., Tormoen, G., Jutric, Z., Young, K., Bahjat, K. S., Gough, M. J., & Crittenden, M. R. (2016). A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. Journal for immunotherapy of cancer, 445. https://doi.org/10.1186/s40425-016-0149-6
Crocenzi, Todd, et al. "A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma." Journal for immunotherapy of cancer vol. 4 (2016): 45. doi: https://doi.org/10.1186/s40425-016-0149-6
Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016. PMID: 27532020; PMCID: PMC4986363.
Copy Download .nbib Format: NLM
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Journal for immunotherapy of cancer

Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD.
PMID: 27532022
J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016.

BACKGROUND: Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash...

Cite
Koelzer VH, Buser T, Willi N, et al. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016;4:47doi: 10.1186/s40425-016-0151-z.
Koelzer, V. H., Buser, T., Willi, N., Rothschild, S. I., Wicki, A., Schiller, P., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016). Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. Journal for immunotherapy of cancer, 447. https://doi.org/10.1186/s40425-016-0151-z
Koelzer, Viktor H, et al. "Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy." Journal for immunotherapy of cancer vol. 4 (2016): 47. doi: https://doi.org/10.1186/s40425-016-0151-z
Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016. PMID: 27532022; PMCID: PMC4986338.
Copy Download .nbib Format: NLM
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.

Journal for immunotherapy of cancer

Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD.
PMID: 25614821
J Immunother Cancer. 2015 Jan 20;3(1):2. doi: 10.1186/s40425-014-0043-z. eCollection 2015.

BACKGROUND: Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require multi-faceted approaches incorporating conventional drug therapies, immunotherapy and...

Cite
Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3(1):2doi: 10.1186/s40425-014-0043-z.
Jing, W., Gershan, J. A., Weber, J., Tlomak, D., McOlash, L., Sabatos-Peyton, C., & Johnson, B. D. (2015). Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. Journal for immunotherapy of cancer, 3(1), 2. https://doi.org/10.1186/s40425-014-0043-z
Jing, Weiqing, et al. "Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma." Journal for immunotherapy of cancer vol. 3,1 (2015): 2. doi: https://doi.org/10.1186/s40425-014-0043-z
Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015 Jan 20;3(1):2. doi: 10.1186/s40425-014-0043-z. eCollection 2015. PMID: 25614821; PMCID: PMC4302511.
Copy Download .nbib Format: NLM
Update on checkpoint blockade therapy for lymphoma.

Journal for immunotherapy of cancer

Kline J, Bishop MR.
PMID: 26199729
J Immunother Cancer. 2015 Jul 21;3:33. doi: 10.1186/s40425-015-0079-8. eCollection 2015.

Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse mechanisms aimed at subverting the host anti-tumor immune response. Tumor immune evasion pathways have been most thoroughly studied in solid tumors. However, emerging...

Cite
Kline J, Bishop MR. Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer. 2015;3:33doi: 10.1186/s40425-015-0079-8.
Kline, J., & Bishop, M. R. (2015). Update on checkpoint blockade therapy for lymphoma. Journal for immunotherapy of cancer, 333. https://doi.org/10.1186/s40425-015-0079-8
Kline, Justin, and Bishop, Michael R. "Update on checkpoint blockade therapy for lymphoma." Journal for immunotherapy of cancer vol. 3 (2015): 33. doi: https://doi.org/10.1186/s40425-015-0079-8
Kline J, Bishop MR. Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer. 2015 Jul 21;3:33. doi: 10.1186/s40425-015-0079-8. eCollection 2015. PMID: 26199729; PMCID: PMC4509696.
Copy Download .nbib Format: NLM
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.

Journal for immunotherapy of cancer

Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M.
PMID: 27190629
J Immunother Cancer. 2016 May 17;4:28. doi: 10.1186/s40425-016-0132-2. eCollection 2016.

BACKGROUND: Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy has demonstrated synergistic survival effects with stereotactic radiosurgery (SRS) in murine GBM. GITR is a co-stimulatory molecule expressed constitutively on regulatory T-cells and by effector T-cells...

Cite
Patel MA, Kim JE, Theodros D, et al. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016;4:28doi: 10.1186/s40425-016-0132-2.
Patel, M. A., Kim, J. E., Theodros, D., Tam, A., Velarde, E., Kochel, C. M., Francica, B., Nirschl, T. R., Ghasemzadeh, A., Mathios, D., Harris-Bookman, S., Jackson, C. C., Jackson, C., Ye, X., Tran, P. T., Tyler, B., Coric, V., Selby, M., Brem, H., Drake, C. G., Pardoll, D. M., & Lim, M. (2016). Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. Journal for immunotherapy of cancer, 428. https://doi.org/10.1186/s40425-016-0132-2
Patel, Mira A, et al. "Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma." Journal for immunotherapy of cancer vol. 4 (2016): 28. doi: https://doi.org/10.1186/s40425-016-0132-2
Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016 May 17;4:28. doi: 10.1186/s40425-016-0132-2. eCollection 2016. PMID: 27190629; PMCID: PMC4869343.
Copy Download .nbib Format: NLM
Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients.

Journal for immunotherapy of cancer

Bailur JK, Derhovanessian E, Gueckel B, Pawelec G.
PMID: 26500775
J Immunother Cancer. 2015 Oct 20;3:45. doi: 10.1186/s40425-015-0090-0. eCollection 2015.

BACKGROUND: Treating elderly breast cancer patients remains a challenge but the increasing availability of immunotherapeutic approaches instills optimism that these tumours may also be susceptible to immune control. Because aging leads to a number of alterations in the immune...

Cite
Bailur JK, Derhovanessian E, Gueckel B, et al. Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer. 2015;3:45doi: 10.1186/s40425-015-0090-0.
Bailur, J. K., Derhovanessian, E., Gueckel, B., & Pawelec, G. (2015). Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. Journal for immunotherapy of cancer, 345. https://doi.org/10.1186/s40425-015-0090-0
Bailur, Jithendra Kini, et al. "Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients." Journal for immunotherapy of cancer vol. 3 (2015): 45. doi: https://doi.org/10.1186/s40425-015-0090-0
Bailur JK, Derhovanessian E, Gueckel B, Pawelec G. Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer. 2015 Oct 20;3:45. doi: 10.1186/s40425-015-0090-0. eCollection 2015. PMID: 26500775; PMCID: PMC4617728.
Copy Download .nbib Format: NLM
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.

Journal for immunotherapy of cancer

Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM.
PMID: 24982761
J Immunother Cancer. 2014 May 13;2:12. doi: 10.1186/2051-1426-2-12. eCollection 2014.

BACKGROUND: The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both trigger innate immune responses that support the induction of tumor-specific immunity. Previous studies showed that these agonists used individually could improve the survival of mice challenged with...

Cite
Zhao BG, Vasilakos JP, Tross D, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014;2:12doi: 10.1186/2051-1426-2-12.
Zhao, B. G., Vasilakos, J. P., Tross, D., Smirnov, D., & Klinman, D. M. (2014). Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. Journal for immunotherapy of cancer, 212. https://doi.org/10.1186/2051-1426-2-12
Zhao, By Gan, et al. "Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors." Journal for immunotherapy of cancer vol. 2 (2014): 12. doi: https://doi.org/10.1186/2051-1426-2-12
Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12. doi: 10.1186/2051-1426-2-12. eCollection 2014. PMID: 24982761; PMCID: PMC4075973.
Copy Download .nbib Format: NLM
Opportunistic infections in patients treated with immunotherapy for cancer.

Journal for immunotherapy of cancer

Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA.
PMID: 24991413
J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014.

Immunomodulatory antibodies that enhance the immune system to fight cancer are revolutionizing the treatment of patients with an expanding variety of malignancies. There is a unique spectrum of side effects associated with immunomodulatory antibodies, termed immune-related adverse events (irAEs),...

Cite
Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19doi: 10.1186/2051-1426-2-19.
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014). Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer, 219. https://doi.org/10.1186/2051-1426-2-19
Kyi, Chrisann, et al. "Opportunistic infections in patients treated with immunotherapy for cancer." Journal for immunotherapy of cancer vol. 2 (2014): 19. doi: https://doi.org/10.1186/2051-1426-2-19
Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014. PMID: 24991413; PMCID: PMC4079190.
Copy Download .nbib Format: NLM
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.

Journal for immunotherapy of cancer

Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED.
PMID: 25516805
J Immunother Cancer. 2014 Dec 16;2(1):41. doi: 10.1186/s40425-014-0041-1. eCollection 2014.

We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous melanoma in the first line setting. She achieved a complete response and then relapsed with metastases to the vitreous cavity with an associated...

Cite
Manusow JS, Khoja L, Pesin N, et al. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer. 2014;2(1):41doi: 10.1186/s40425-014-0041-1.
Manusow, J. S., Khoja, L., Pesin, N., Joshua, A. M., & Mandelcorn, E. D. (2014). Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. Journal for immunotherapy of cancer, 2(1), 41. https://doi.org/10.1186/s40425-014-0041-1
Manusow, Joshua S, et al. "Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma." Journal for immunotherapy of cancer vol. 2,1 (2014): 41. doi: https://doi.org/10.1186/s40425-014-0041-1
Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer. 2014 Dec 16;2(1):41. doi: 10.1186/s40425-014-0041-1. eCollection 2014. PMID: 25516805; PMCID: PMC4266968.
Copy Download .nbib Format: NLM
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.

Journal for immunotherapy of cancer

Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA.
PMID: 25516806
J Immunother Cancer. 2014 Dec 16;2(1):42. doi: 10.1186/s40425-014-0042-0. eCollection 2014.

BACKGROUND: Assessment of therapeutic activity of drugs blocking immune checkpoints such as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear anew before regressing, due to intratumoral inflammation. We assessed whether circulating tumor DNA...

Cite
Lipson EJ, Velculescu VE, Pritchard TS, et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2(1):42doi: 10.1186/s40425-014-0042-0.
Lipson, E. J., Velculescu, V. E., Pritchard, T. S., Sausen, M., Pardoll, D. M., Topalian, S. L., & Diaz, L. A. (2014). Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. Journal for immunotherapy of cancer, 2(1), 42. https://doi.org/10.1186/s40425-014-0042-0
Lipson, Evan J, et al. "Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade." Journal for immunotherapy of cancer vol. 2,1 (2014): 42. doi: https://doi.org/10.1186/s40425-014-0042-0
Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014 Dec 16;2(1):42. doi: 10.1186/s40425-014-0042-0. eCollection 2014. PMID: 25516806; PMCID: PMC4267741.
Copy Download .nbib Format: NLM
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

Journal for immunotherapy of cancer

Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL.
PMID: 25992289
J Immunother Cancer. 2015 May 19;3:18. doi: 10.1186/s40425-015-0063-3. eCollection 2015.

BACKGROUND: Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 and cytotoxic T lymphocyte antigen 4 (CTLA-4)...

Cite
Kohlhapp FJ, Broucek JR, Hughes T, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015;3:18doi: 10.1186/s40425-015-0063-3.
Kohlhapp, F. J., Broucek, J. R., Hughes, T., Huelsmann, E. J., Lusciks, J., Zayas, J. P., Dolubizno, H., Fleetwood, V. A., Grin, A., Hill, G. E., Poshepny, J. L., Nabatiyan, A., Ruby, C. E., Snook, J. D., Rudra, J. S., Schenkel, J. M., Masopust, D., Zloza, A., & Kaufman, H. L. (2015). NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal for immunotherapy of cancer, 318. https://doi.org/10.1186/s40425-015-0063-3
Kohlhapp, Frederick J, et al. "NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade." Journal for immunotherapy of cancer vol. 3 (2015): 18. doi: https://doi.org/10.1186/s40425-015-0063-3
Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015 May 19;3:18. doi: 10.1186/s40425-015-0063-3. eCollection 2015. PMID: 25992289; PMCID: PMC4437746.
Copy Download .nbib Format: NLM
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.

Journal for immunotherapy of cancer

Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID.
PMID: 26672895
J Immunother Cancer. 2015 Dec 15;3:50. doi: 10.1186/s40425-015-0095-8. eCollection 2015.

BACKGROUND: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore, outcomes following ipilimumab and radiation are of interest, especially given case...

Cite
Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50doi: 10.1186/s40425-015-0095-8.
Schoenfeld, J. D., Mahadevan, A., Floyd, S. R., Dyer, M. A., Catalano, P. J., Alexander, B. M., McDermott, D. F., & Kaplan, I. D. (2015). Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. Journal for immunotherapy of cancer, 350. https://doi.org/10.1186/s40425-015-0095-8
Schoenfeld, Jonathan D, et al. "Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review." Journal for immunotherapy of cancer vol. 3 (2015): 50. doi: https://doi.org/10.1186/s40425-015-0095-8
Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015 Dec 15;3:50. doi: 10.1186/s40425-015-0095-8. eCollection 2015. PMID: 26672895; PMCID: PMC4678639.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 975 entries